tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Novartis AG

NVS
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
159.990USD
-3.100-1.90%
์ข…๊ฐ€ย 09-04 16:00๏ผˆET๏ผ‰
304.10B์‹œ๊ฐ€์ด์•ก
22.77P/E TTM

NVS ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Novartis AG์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋А ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Novartis AG ์‹ค์  ๋ฐœํ‘œ์ผ

์ตœ์‹  ์ถœ์‹œ
Jul 21, 2026
EPS / ์˜ˆ์ƒ
1.71/2.36
์ˆ˜์ต / ์˜ˆ์ƒ
14.95B/14.50B
์ฃผ๊ธฐ
FY2025 ์žฌ๋ฌด์ œํ‘œ
์ˆ˜์ต(YoY)
56.33B
8.91%
EPS(YoY)
7.21
21.88%
์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€
HOLD
2026/09/06
๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
YOY
๋นˆ ํ–‰ ์ˆจ๊ธฐ๊ธฐ
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
์žฌ๋ฌด ์ง€ํ‘œ
EPS
-17.40%1.71
-10.10%1.65
-11.39%1.26
28.67%2.04
29.92%2.07
39.33%1.83
-65.63%1.42
85.59%1.58
43.60%1.60
21.01%1.32
501.83%4.13
--0.85
--1.11
--1.09
--0.69
--2.50
----
----
----
----
์ˆ˜์ต
2.88%14.95B
-0.54%13.51B
2.23%13.86B
9.00%14.36B
12.86%14.53B
12.09%13.59B
15.13%13.56B
8.93%13.17B
9.60%12.87B
9.71%12.12B
8.24%11.78B
12.14%12.09B
-10.24%11.74B
-13.79%11.05B
135.55%10.88B
-19.33%10.78B
-1.57%13.09B
0.95%12.81B
-64.55%4.62B
6.61%13.37B
์ˆœ์ด์ต
-19.23%3.26B
-12.48%3.16B
-14.51%2.41B
23.17%3.93B
24.49%4.04B
34.15%3.61B
-66.77%2.82B
81.09%3.19B
40.16%3.25B
17.23%2.69B
478.44%8.48B
11.95%1.76B
36.72%2.32B
3.20%2.29B
-91.01%1.47B
-42.97%1.57B
-41.51%1.69B
7.92%2.22B
678.80%16.31B
42.53%2.76B
์ˆœ์ด์ต๋ฅ 
-21.33%21.79%
-12.07%23.36%
-16.61%17.34%
13.20%27.37%
9.84%27.70%
19.78%26.57%
-7.15%20.80%
93.25%24.18%
30.42%25.22%
13.95%22.18%
85.34%22.40%
--12.51%
--19.34%
--19.46%
--12.09%
--14.57%
----
----
----
----
์ด ์ด์ต๋ฅ 
-2.28%75.39%
-2.25%74.55%
-1.47%74.44%
-0.02%75.38%
2.35%77.15%
2.38%76.27%
1.24%75.56%
1.58%75.39%
5.36%75.38%
2.16%74.50%
3.59%74.63%
--74.22%
--71.55%
--72.92%
--72.05%
--73.72%
----
----
----
----
๋ถ€์ฑ„๋น„์œจ
29.28%40.07%
26.70%39.53%
4.30%31.88%
-3.92%29.78%
4.46%31.00%
8.22%31.20%
15.97%30.57%
39.03%30.99%
16.36%29.67%
11.00%28.83%
10.94%26.36%
--22.29%
--25.50%
--25.97%
--23.76%
--24.01%
----
----
----
----
์ˆ˜์ต
2.88%14.95B
-0.54%13.51B
2.23%13.86B
9.00%14.36B
12.86%14.53B
12.09%13.59B
15.13%13.56B
8.93%13.17B
9.60%12.87B
9.71%12.12B
8.24%11.78B
12.14%12.09B
-10.24%11.74B
-13.79%11.05B
135.55%10.88B
-19.33%10.78B
-1.57%13.09B
0.95%12.81B
-64.55%4.62B
6.61%13.37B
์˜์—… ์ด์ต
0.00%5.16B
-14.09%4.11B
-0.81%4.06B
5.71%4.59B
22.81%5.16B
28.01%4.79B
36.57%4.10B
25.64%4.35B
26.01%4.20B
28.82%3.74B
9.49%3.00B
55.95%3.46B
0.30%3.33B
-10.73%2.90B
139.72%2.74B
-37.27%2.22B
-2.35%3.32B
8.29%3.25B
-56.92%1.14B
6.31%3.54B
์ˆœ์ด์ต
-19.23%3.26B
-12.48%3.16B
-14.51%2.41B
23.17%3.93B
24.49%4.04B
34.15%3.61B
-66.77%2.82B
81.09%3.19B
40.16%3.25B
17.23%2.69B
478.44%8.48B
11.95%1.76B
36.72%2.32B
3.20%2.29B
-91.01%1.47B
-42.97%1.57B
-41.51%1.69B
7.92%2.22B
678.80%16.31B
42.53%2.76B
์œ ๋™์ž์‚ฐ
5.44%27.35B
5.97%26.61B
2.55%30.46B
-9.81%28.20B
0.96%25.94B
-5.06%25.11B
-2.55%29.70B
-31.53%31.26B
-23.29%25.69B
-17.65%26.45B
-17.42%30.48B
23.56%45.66B
-12.19%33.49B
-13.76%32.11B
-19.27%36.91B
40.76%36.95B
60.21%38.14B
67.74%37.24B
54.07%45.72B
-9.39%26.25B
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
0.11%31.75B
-0.77%31.37B
-4.93%27.28B
13.75%32.00B
14.86%31.71B
7.96%31.62B
8.72%28.69B
-41.87%28.13B
-13.47%27.61B
-4.13%29.29B
-7.91%26.39B
71.85%48.39B
15.42%31.91B
2.49%30.55B
-5.14%28.66B
-5.76%28.16B
-6.71%27.65B
-1.17%29.81B
-8.62%30.21B
-6.15%29.88B
์ด ์ž์‚ฐ
16.90%122.03B
18.60%118.53B
8.51%110.95B
3.64%107.29B
7.07%104.39B
5.94%99.94B
2.30%102.25B
-8.14%103.52B
-12.14%97.50B
-15.95%94.33B
-14.91%99.94B
-4.87%112.70B
-9.71%110.98B
-10.36%112.24B
-10.88%117.45B
-2.26%118.46B
-0.89%122.91B
2.85%125.22B
3.14%131.79B
-6.53%121.21B
๋ถ€์ฑ„ ์ด๊ณ„
28.47%80.09B
29.46%79.61B
10.81%64.40B
4.08%62.54B
12.12%62.34B
12.66%61.49B
9.26%58.12B
-19.30%60.08B
-5.83%55.60B
-9.19%54.58B
-8.33%53.20B
29.33%74.45B
-1.43%59.05B
-5.38%60.10B
-9.29%58.03B
-10.43%57.57B
-14.28%59.90B
-10.75%63.51B
-10.04%63.97B
-14.45%64.27B
์ž๋ณธ ์ด๊ณ„
-0.26%41.95B
1.24%38.93B
5.49%46.55B
3.02%44.75B
0.36%42.05B
-3.28%38.45B
-5.61%44.13B
13.59%43.44B
-19.31%41.90B
-23.75%39.76B
-21.33%46.75B
-37.20%38.24B
-17.58%51.93B
-15.50%52.14B
-12.38%59.42B
6.96%60.90B
16.40%63.01B
21.97%61.70B
19.69%67.82B
4.37%56.94B
์ˆœ์˜์—…์ด์ต
-11.73%5.88B
0.85%3.68B
-46.01%2.26B
4.53%6.57B
36.70%6.66B
60.93%3.65B
64.63%4.19B
18.51%6.29B
36.33%4.88B
-23.40%2.27B
-38.04%2.55B
12.35%5.30B
-4.77%3.58B
79.32%2.96B
5.84%4.11B
-4.14%4.72B
-9.12%3.75B
-22.58%1.65B
-3.02%3.88B
56.05%4.92B
์ˆœํˆฌ์ž
-38.43%-3.10B
-3656.36%-11.74B
30.63%-2.10B
-129.95%-860.00M
30.06%-2.24B
136.71%330.00M
-196.77%-3.03B
81.34%-374.00M
-204.56%-3.21B
-108.46%-899.00M
30.33%-1.02B
-138.55%-2.00B
90.94%-1.05B
13.41%10.62B
-132.15%-1.47B
519.87%5.20B
-11965.31%-11.63B
1092.99%9.37B
901.93%4.56B
38.86%-1.24B
์ˆœ์žฌ๋ฌดํ™œ๋™
61.25%-2.02B
141.87%3.58B
156.17%1.68B
-630.10%-2.79B
-62.91%-5.21B
-65.53%-8.55B
-504.03%-3.00B
91.13%-382.00M
12.02%-3.20B
43.88%-5.16B
87.58%-496.00M
9.12%-4.31B
-57.99%-3.64B
3.42%-9.20B
-22.85%-3.99B
-206.07%-4.74B
21.59%-2.30B
-11.71%-9.53B
-11.22%-3.25B
-181.00%-1.55B

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Novartis AG์˜ ์ด์ˆ˜์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ๋งค์ถœ์€ 56.33B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 51.72B์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 30.46B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 2.55์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novartis AG์˜ ์ด์ž์‚ฐ์€ 110.95B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 8.51์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novartis AG์˜ ์ด๋ถ€์ฑ„๋Š” 64.40B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 10.81์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novartis AG์˜ ์ด์ž๋ณธ์€ 46.55B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 5.49์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novartis AG์˜ ์ˆœ์˜์—…์†Œ๋“์€ 18.72B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 14.42์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novartis AG์˜ ์ˆœํˆฌ์ž๋Š” -4.88B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 35.09์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Novartis AG์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ -14.87B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -26.61์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ 7.21์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 21.88์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ 13.98B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 17.11์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ˆœ์ด์ต๋ฅ ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต๋ฅ ์€ 24.79์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 7.42์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ๋งค์ถœ์ด์ด์ต๋ฅ ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ๋งค์ถœ์ด์ด์ต๋ฅ ์€ 75.82์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 0.79์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ๋ถ€์ฑ„/์ž์‚ฐ ๋น„์œจ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ๋ถ€์ฑ„/์ž์‚ฐ ๋น„์œจ์€ 31.88์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 4.30์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ 31.01์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 17.81์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ 13.10์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 10.95์ž…๋‹ˆ๋‹ค.

Novartis AG์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Novartis AG์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ 18.72B์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 14.42์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ